Review



rabbit anti atf3  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Novus Biologicals rabbit anti atf3
    Rabbit Anti Atf3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF3+Antibody/pmc13674489-272-13-15
    Average 93 stars, based on 42 article reviews
    rabbit anti atf3 - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Control:

    Article Title: Key role for Rac in the early transcriptional response to extracellular matrix stiffness and stiffness-dependent repression of ATF3
    Article Snippet: .. The membranes were saturated with 5% BSA in 1× TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) with 0.1% Tween-20 and probed with primary antibodies to ATF3 (1:200, sc-188, Santa Cruz Biotechnology or 1:500, NBP1-85816, Novus Biologicals), cyclin D1 (1:200, sc-20044, Santa Cruz Biotechnology or 1:500, 681902, BioLegend), Rac1/2/3 (1:100, 2465, Cell Signaling Technology), RhoA/B/C (1:200, MA1-011, Thermo Fisher Scientific) or GAPDH (loading control; 1:1000, MA5-15738, Thermo Fisher Scientific). .. The membranes were saturated with 5% BSA in 1× TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) with 0.1% Tween-20 and probed with primary antibodies to ATF3 (1:200, sc-188, Santa Cruz Biotechnology or 1:500, NBP1-85816, Novus Biologicals), cyclin D1 (1:200, sc-20044, Santa Cruz Biotechnology or 1:500, 681902, BioLegend), Rac1/2/3 (1:100, 2465, Cell Signaling Technology), RhoA/B/C (1:200, MA1-011, Thermo Fisher Scientific) or GAPDH (loading control; 1:1000, MA5-15738, Thermo Fisher Scientific).

    Article Title: Key role for Rac in the early transcriptional response to extracellular matrix stiffness and stiffness-dependent repression of ATF3.
    Article Snippet: .. The membranes were saturated with 5% BSA in 1× TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) with 0.1% Tween-20 and probed with primary antibodies to ATF3 (1:200, sc-188, Santa Cruz Biotechnology or 1:500, NBP1-85816, Novus Biologicals), cyclin D1 (1:200, sc-20044, Santa Cruz Biotechnology or 1:500, 681902, BioLegend), Rac1/2/3 (1:100, 2465, Cell Signaling Technology), RhoA/B/C (1:200, MA1-011, Thermo Fisher Scientific) or GAPDH (loading control; 1:1000, MA5-15738, Thermo Fisher Scientific). .. The secondary antibodies used were ECL anti-rabbit HRP (1:500, 3144, GE Healthcare) and ECL anti-rabbit HRP (1:500, 3143, GE Healthcare).



    Similar Products

    94
    Bioss rabbit anti atf3 antibody
    Rabbit Anti Atf3 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF3+Polyclonal+Antibody/10__1007_slash_s00018___026___06410___y-112-10-14
    Average 94 stars, based on 1 article reviews
    rabbit anti atf3 antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Novus Biologicals rabbit anti atf3
    Rabbit Anti Atf3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF3+Antibody/pmc13674489-272-13-15
    Average 93 stars, based on 1 article reviews
    rabbit anti atf3 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology atf3
    Atf3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF-3+Antibody/pmc13675185-371-168-169
    Average 94 stars, based on 1 article reviews
    atf3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology anti atf3 antibody
    Anti Atf3 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF-3+Antibody/10__1007_slash_s00018___026___06410___y-133-6-9
    Average 94 stars, based on 1 article reviews
    anti atf3 antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology obesity primary antibodies against atf3
    Obesity Primary Antibodies Against Atf3, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF3+Rabbit+pAb/pm42469432-92-26-31
    Average 94 stars, based on 1 article reviews
    obesity primary antibodies against atf3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    OriGene atf3
    Atf3, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF3+Mouse+Monoclonal+Antibody/pm42209734-46-55-57
    Average 94 stars, based on 1 article reviews
    atf3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology antibodies against atf3
    Expression and diagnostic significance of <t>ATF3</t> in pan-cancer. A ATF3 expression in normal and cancer samples analyzed with the GTEx and TCGA datasets. B Receiver operating characteristic (ROC) analysis evaluated the diagnostic performance of ATF3 across cancer types. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001
    Antibodies Against Atf3, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF3+Rabbit+pAb/pmc13129119-55-22-26
    Average 94 stars, based on 1 article reviews
    antibodies against atf3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Novus Biologicals anti atf3
    Expression and diagnostic significance of <t>ATF3</t> in pan-cancer. A ATF3 expression in normal and cancer samples analyzed with the GTEx and TCGA datasets. B Receiver operating characteristic (ROC) analysis evaluated the diagnostic performance of ATF3 across cancer types. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001
    Anti Atf3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF3+Antibody/bio_rxiv__64898__2026__04__01__715652-269-13-16
    Average 93 stars, based on 1 article reviews
    anti atf3 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology anti atf3
    Expression and diagnostic significance of <t>ATF3</t> in pan-cancer. A ATF3 expression in normal and cancer samples analyzed with the GTEx and TCGA datasets. B Receiver operating characteristic (ROC) analysis evaluated the diagnostic performance of ATF3 across cancer types. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001
    Anti Atf3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibodies+to+atf3/ATF-3+Antibody/bio_rxiv__64898__2026__02__23__707492-338-12-13
    Average 94 stars, based on 1 article reviews
    anti atf3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Expression and diagnostic significance of ATF3 in pan-cancer. A ATF3 expression in normal and cancer samples analyzed with the GTEx and TCGA datasets. B Receiver operating characteristic (ROC) analysis evaluated the diagnostic performance of ATF3 across cancer types. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001

    Journal: Discover Oncology

    Article Title: Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma

    doi: 10.1007/s12672-026-05113-x

    Figure Lengend Snippet: Expression and diagnostic significance of ATF3 in pan-cancer. A ATF3 expression in normal and cancer samples analyzed with the GTEx and TCGA datasets. B Receiver operating characteristic (ROC) analysis evaluated the diagnostic performance of ATF3 across cancer types. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001

    Article Snippet: After 30 min of blocking with 5% non-fat milk, the membranes were incubated for the whole night at 4 °C with primary antibodies against ATF3 (1:500, ABclonal) and GAPDH (1:10,000, ABclonal).

    Techniques: Expressing, Diagnostic Assay

    Prognostic evaluation of ATF3 in pan-cancer. A – D Univariate Cox regression analyses of ATF3 in different tumors for disease-free interval (DFI) ( A ), disease-specific survival (DSS) ( B ), overall survival (OS) ( C ) and progression-free interval (PFI) ( D ). E – H Patients were stratified by the median ATF3 expression; Kaplan-Meier curves compared the impact of high vs. low ATF3 expression on DFI ( E ), DSS ( F ), OS ( G ) and PFI ( H ) in each cancer type. HR, hazard ratio; CI, confidence interval

    Journal: Discover Oncology

    Article Title: Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma

    doi: 10.1007/s12672-026-05113-x

    Figure Lengend Snippet: Prognostic evaluation of ATF3 in pan-cancer. A – D Univariate Cox regression analyses of ATF3 in different tumors for disease-free interval (DFI) ( A ), disease-specific survival (DSS) ( B ), overall survival (OS) ( C ) and progression-free interval (PFI) ( D ). E – H Patients were stratified by the median ATF3 expression; Kaplan-Meier curves compared the impact of high vs. low ATF3 expression on DFI ( E ), DSS ( F ), OS ( G ) and PFI ( H ) in each cancer type. HR, hazard ratio; CI, confidence interval

    Article Snippet: After 30 min of blocking with 5% non-fat milk, the membranes were incubated for the whole night at 4 °C with primary antibodies against ATF3 (1:500, ABclonal) and GAPDH (1:10,000, ABclonal).

    Techniques: Expressing

    Mutation landscape and mutation-load analysis of ATF3 in pan-cancer. A Frequencies of distinct ATF3 mutation types across cancers. B Analysis showing that missense mutations (green) were the predominant ATF3 alteration. C Radar plot depicting the correlation between ATF3 expression and tumor mutation burden (TMB). D Radar plot depicting the correlation between ATF3 expression and microsatellite instability (MSI). *, P < 0.05; **, P < 0.01

    Journal: Discover Oncology

    Article Title: Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma

    doi: 10.1007/s12672-026-05113-x

    Figure Lengend Snippet: Mutation landscape and mutation-load analysis of ATF3 in pan-cancer. A Frequencies of distinct ATF3 mutation types across cancers. B Analysis showing that missense mutations (green) were the predominant ATF3 alteration. C Radar plot depicting the correlation between ATF3 expression and tumor mutation burden (TMB). D Radar plot depicting the correlation between ATF3 expression and microsatellite instability (MSI). *, P < 0.05; **, P < 0.01

    Article Snippet: After 30 min of blocking with 5% non-fat milk, the membranes were incubated for the whole night at 4 °C with primary antibodies against ATF3 (1:500, ABclonal) and GAPDH (1:10,000, ABclonal).

    Techniques: Mutagenesis, Expressing

    Relationship between ATF3 expression and immunity/differentially methylated probes-based stemness index (DMPsi). A ESTIMATE analysis of the association between ATF3 expression and ImmuneScore, StromalScore, and EstimateScore. B – F Correlations of ATF3 expression with immune-checkpoint genes ( B ), chemokines (C), immune inhibitors (D), immune stimulators (E) and chemokines receptors (F). G Correlations between ATF3 and mismatch-repair and DNA-methyltransferase genes. H Correlation between ATF3 and DMPsi. *, P < 0.05; **, P < 0.01; ***, P < 0.001

    Journal: Discover Oncology

    Article Title: Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma

    doi: 10.1007/s12672-026-05113-x

    Figure Lengend Snippet: Relationship between ATF3 expression and immunity/differentially methylated probes-based stemness index (DMPsi). A ESTIMATE analysis of the association between ATF3 expression and ImmuneScore, StromalScore, and EstimateScore. B – F Correlations of ATF3 expression with immune-checkpoint genes ( B ), chemokines (C), immune inhibitors (D), immune stimulators (E) and chemokines receptors (F). G Correlations between ATF3 and mismatch-repair and DNA-methyltransferase genes. H Correlation between ATF3 and DMPsi. *, P < 0.05; **, P < 0.01; ***, P < 0.001

    Article Snippet: After 30 min of blocking with 5% non-fat milk, the membranes were incubated for the whole night at 4 °C with primary antibodies against ATF3 (1:500, ABclonal) and GAPDH (1:10,000, ABclonal).

    Techniques: Expressing, Methylation

    ATF3 was down-regulated in kidney clear cell renal cell carcinoma (KIRC) and associated with favorable prognosis. A – C ATF3 expression in KIRC cell lines determined by real-time quantitative polymerase chain reaction (RT-qPCR) ( A ), Western blot ( B ) and immunofluorescence ( C ). D Kaplan-Meier survival curves comparing high vs. low ATF3 expression for DFI, DSS, OS and PFI in KIRC. E Association between ATF3 and clinical-feature subgroups in KIRC. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001

    Journal: Discover Oncology

    Article Title: Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma

    doi: 10.1007/s12672-026-05113-x

    Figure Lengend Snippet: ATF3 was down-regulated in kidney clear cell renal cell carcinoma (KIRC) and associated with favorable prognosis. A – C ATF3 expression in KIRC cell lines determined by real-time quantitative polymerase chain reaction (RT-qPCR) ( A ), Western blot ( B ) and immunofluorescence ( C ). D Kaplan-Meier survival curves comparing high vs. low ATF3 expression for DFI, DSS, OS and PFI in KIRC. E Association between ATF3 and clinical-feature subgroups in KIRC. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001

    Article Snippet: After 30 min of blocking with 5% non-fat milk, the membranes were incubated for the whole night at 4 °C with primary antibodies against ATF3 (1:500, ABclonal) and GAPDH (1:10,000, ABclonal).

    Techniques: Expressing, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Western Blot, Immunofluorescence

    Enrichment and immune-infiltration analyses of ATF3. A Volcano plot of differentially expressed genes (DEGs) between high and low ATF3 groups. B Heat-map of the DEGs. C Gene Ontology (GO) enrichment of the DEGs. BP, Biological Process; CC, Cellular Component; MF, Molecular Function. D Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment of the DEGs. E Gene set enrichment analysis (GSEA) of ATF3. F Stacked bar chart of immune-cell scores in high and low ATF3 groups. G Box plot showing differences in immune-cell infiltration between the two groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001

    Journal: Discover Oncology

    Article Title: Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma

    doi: 10.1007/s12672-026-05113-x

    Figure Lengend Snippet: Enrichment and immune-infiltration analyses of ATF3. A Volcano plot of differentially expressed genes (DEGs) between high and low ATF3 groups. B Heat-map of the DEGs. C Gene Ontology (GO) enrichment of the DEGs. BP, Biological Process; CC, Cellular Component; MF, Molecular Function. D Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment of the DEGs. E Gene set enrichment analysis (GSEA) of ATF3. F Stacked bar chart of immune-cell scores in high and low ATF3 groups. G Box plot showing differences in immune-cell infiltration between the two groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001

    Article Snippet: After 30 min of blocking with 5% non-fat milk, the membranes were incubated for the whole night at 4 °C with primary antibodies against ATF3 (1:500, ABclonal) and GAPDH (1:10,000, ABclonal).

    Techniques:

    Prediction of ATF3-targeted drugs. A Drug-sensitivity analysis between high and low ATF3 groups (top 10 agents). B ATF3-drug network. C Molecular-docking affinity between progesterone and ATF3

    Journal: Discover Oncology

    Article Title: Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma

    doi: 10.1007/s12672-026-05113-x

    Figure Lengend Snippet: Prediction of ATF3-targeted drugs. A Drug-sensitivity analysis between high and low ATF3 groups (top 10 agents). B ATF3-drug network. C Molecular-docking affinity between progesterone and ATF3

    Article Snippet: After 30 min of blocking with 5% non-fat milk, the membranes were incubated for the whole night at 4 °C with primary antibodies against ATF3 (1:500, ABclonal) and GAPDH (1:10,000, ABclonal).

    Techniques:

    Single-cell RNA sequencing (scRNA-seq) analysis of ATF3 in KIRC. A Uniform Manifold Approximation and Projection (UMAP) showing cell annotations. B Proportions of annotated cells in KIRC vs. control. C ATF3 expression across cell types in KIRC vs. control. D Pseudotime trajectory of endothelial-afferent/efferent arterioles/descending vasa recta (AEAs/DVR) divided into three stages. E Distribution of KIRC and control samples along the AEAs/DVR differentiation trajectory. F ATF3 expression during AEAs/DVR differentiation. G Cell-cell communication analysis. *, P < 0.05; **, P < 0.01; ****, P < 0.0001

    Journal: Discover Oncology

    Article Title: Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma

    doi: 10.1007/s12672-026-05113-x

    Figure Lengend Snippet: Single-cell RNA sequencing (scRNA-seq) analysis of ATF3 in KIRC. A Uniform Manifold Approximation and Projection (UMAP) showing cell annotations. B Proportions of annotated cells in KIRC vs. control. C ATF3 expression across cell types in KIRC vs. control. D Pseudotime trajectory of endothelial-afferent/efferent arterioles/descending vasa recta (AEAs/DVR) divided into three stages. E Distribution of KIRC and control samples along the AEAs/DVR differentiation trajectory. F ATF3 expression during AEAs/DVR differentiation. G Cell-cell communication analysis. *, P < 0.05; **, P < 0.01; ****, P < 0.0001

    Article Snippet: After 30 min of blocking with 5% non-fat milk, the membranes were incubated for the whole night at 4 °C with primary antibodies against ATF3 (1:500, ABclonal) and GAPDH (1:10,000, ABclonal).

    Techniques: Single Cell, RNA Sequencing, Control, Expressing